Dopamine is thought to exert a negative control on lactotrop cell proliferation and prolactin production. Indeed, mice lacking the D2 receptor develop pituitary tumors of lactotrop origin. Because lactotrops express two isoforms of D2R, D2L, and D2S, in a specific ratio, we decided to explore the physiological importance of their relative abundance in vivo. Thus, we generated transgenic animals overexpressing either D2L or D2S in lactotrops. Increased expression of D2S, but not of D2L, leads to mitogen-activated protein kinase (MAPK) induction, which results in pituitary hypoplasia. On the other hand, levels of phosphorylated MAPKs are drastically reduced in pituitary tumors generated by the absence of D2-dependent signaling. These results underline a critical role of D2-mediated MAPK activation in lactotrop proliferation. Furthermore, whereas D2S overexpression results to a drastic reduction of prolactin, D2L overexpression elevates it. Our findings underscore a different role of the two D2R isoforms in the pituitary gland physiology.
Dopamine is thought to exert a negative control on lactotrop cell proliferation and prolactin production. Indeed, mice lacking the D2 receptor develop pituitary tumors of lactotrop origin. Because lactotrops express two isoforms of D2R, D2L, and D2S, in a specific ratio, we decided to explore the physiological importance of their relative abundance in vivo. Thus, we generated transgenic animals overexpressing either D2L or D2S in lactotrops. Increased expression of D2S, but not of D2L, leads to mitogen-activated protein kinase (MAPK) induction, which results in pituitary hypoplasia. On the other hand, levels of phosphorylated MAPKs are drastically reduced in pituitary tumors generated by the absence of D2-dependent signaling. These results underline a critical role of D2-mediated MAPK activation in lactotrop proliferation. Furthermore, whereas D2S overexpression results to a drastic reduction of prolactin, D2L overexpression elevates it. Our findings underscore a different role of the two D2R isoforms in the pituitary gland physiology.
DA ͉ D2L and D2S receptors ͉ pituitary ͉ MAPK A ctivation of dopamine D2 receptor (D2R) regulates several physiological functions in the central nervous system as well as in the pituitary gland (1) (2) (3) . In the pituitary, the signal transduction activated by D2 receptors negatively regulates prolactin (PRL) synthesis and release (4, 5) . Analyses of D2R null mice have illustrated a control on the proliferative rate of lactotrops by D2R. In the absence of D2R signaling pituitary tumors arise of lactotrop origin (prolactinomas) in 100% of aged females and only very rarely in males (2, 6, 7) . In humans, prolactinomas might regress on treatment with dopaminergic agonists such as bromocriptine and are generally more common in women than in men (8, 9) . Thus, similar D2R-mediated signaling seems to exist at the pituitary level in humans and mice. It is presently unclear through which pathway the activation of D2R is able to control lactotrop proliferation.
D2Rs exist into two molecularly distinct isoforms, D2L and D2S. Both isoforms, generated by alternative splicing from the same gene, have similar pharmacological and biochemical profiles in vitro, despite the presence of an additional 29 amino acids in the D2L isoform (10) (11) (12) (13) . This additional segment is located in the third intracellular loop of the putative receptor structure, a region involved in the coupling to the G proteins. In vitro studies suggest that the two isoforms might activate different signaling pathways in vivo (14) . Analyses with genetically modified mice have recently supported the hypothesis that D2L and D2S might have different functions in vivo (15, 16) .
The two isoforms are produced in a well-defined D2L͞D2S ratio. The D2L isoform is always more abundant than D2S. This ratio is respected in the pituitary and in the brain with the exception of mesencephalic regions where it is inverted (13, 17) . The physiological role of the ratio of the two different isoforms is still unknown. In this study, we have addressed this point by analyzing the consequence of altering the expression of D2L and D2S on lactotrops physiology, both at the cellular and biochemical levels.
We have generated transgenic animals overexpressing either isoform of the D2R in the lactotrops and analyzed how D2-mediated signaling affects lactotrop proliferation both in vivo and in vitro. We show that stimulation of D2R leads to the activation of p44͞42 extracellular-regulated kinase (ERKs) of the mitogen-activated protein kinase (MAPK) pathway in the pituitary. We show that D2L and D2S differentially activate this pathway. ERKs activation is correlated with an inhibition of lactotrop proliferation both in vitro and in vivo. Indeed, the development of prolactinomas found in aged D2R-null female mice is accompanied by a concomitant decrease in the phosphorylation of these kinases. Thus, these studies clearly show an antagonistic effect of ERK activation mediated by D2R on lactotrop proliferation.
Materials and Methods
Generation of D2L and D2S Transgenic Lines. Transgenic lines were generated by using a 3,033-bp fragment (BamHI-HindIII) of the PRL gene promoter (Ϫ3,000͞ϩ33) (18) . The fragment was ligated to D2L or D2S cDNA (13), respectively, of 2,261 and 2,174 bp. Finally a fragment of 847 bp (BamHI-BglII) corresponding to the simian virus 40 (SV40) late polyadenylation site (19) was cloned at the 3Ј of PRL-D2L or PRL-D2S (Fig. 1) . Both constructs were injected in C57BL6͞SJL fertilized oocytes. The transgenic animals used in this study are in a pure C57͞BL6 background. Transgenics were identified by Southern blot analysis of tail biopsies of genomic DNA digested with PstI. Blots were hybridized with a random primed 32 P-labeled probe corresponding to the SV40 late polyadenylation site. The number of copies of the transgene was evaluated by comparing dot-blot analysis of transgenic DNA with injected fragment (20) . D2R knockout (1) had a mixed 129Sv ϫ C57BL͞6 genetic background, with a 75% contribution of C57BL͞6. Animals were housed in a 12-h light͞dark cycle with food and water available ad libitum. All of the experiments were performed with female mice.
on formaldehyde͞agarose gel in 10 mM sodium phosphate buffer and transferred to Hybond Nϩ (Amersham Pharmacia). Membranes were hybridized overnight at 42°C in 50% formamide, washed 10 min two times at room temperature and two times at 60°C under high stringent conditions (2ϫ SSC͞0.1% SDS), and then exposed to Kodak X-Omat films. RNase protections assays and PCR were performed as described (15, 21) . Binding assays were performed as described (15) ; in brief 15 g of pituitary membranes were used for ligand-binding assays with [ In Situ Hybridization and Immunofluorescence. Pituitary cryostat sections (10 m) were prepared from 4-month-old WT and PRL-D2L or PRL-D2S female mice. In situ hybridization was performed as described (2) . After antisense RNA hybridization and washing, the cryostat sections were dipped in Kodak NTB-2 autoradiography emulsion and exposed for 24 h. Nuclei were counterstained by using toluidine blue. The specificity of in situ hybridization results was confirmed by absence of detectable signals with the sense riboprobes.
For immunofluorescence pituitary, cryostat sections were postfixed in formalin (Sigma) for 15 min, preincubated 1 h in 5% normal goat serum and 0.05% Tween 20 in PBS 1ϫ, followed by incubation with rabbit anti-PRL antibody (1:2,000) (Euromedex Mundolsheim, France) at 4°C overnight. Slides were then incubated 1 h with goat anti-rabbit conjugated with Cy3 (1:1,000) (Jackson ImmunoResearch All of the inhibitors (U0126 at 10 M, PD98059 at 50 M, SB203580 at 5 M, Ro318220 at 1 M, and haloperidol 10 M) were added 1 h before bromocriptine or PMA treatment. U0126, PD98059, SB203580, and Ro318220 were from Calbiochem. Bromocriptine, PMA, and haloperidol were from Sigma.
Immunoblotting Analysis. Pituitary anterior lobes were rapidly dissected, frozen, and homogenized directly in 50 l of Laemmli buffer (22) . Protein extracts were resolved by standard SDS͞ PAGE and quantified by Coomassie blue staining. Samples were electroblotted onto Protan nitrocellulose (Schleicher & Schuell). Membranes were incubated in PBS͞5% low-fat milk and the appropriate antibody for 16 h at 4°C. Donkey, anti-rabbithorseradish peroxidase (Jackson) antibodies were used to reveal immunocomplexes by enhanced chemioluminescence (ECL; Amersham Pharmacia). After P-ERK incubation and Western blot analysis the membranes were stripped and incubated with ERK. ERK and P-ERK (New England Biolabs) were used at 1:1,000. Protein bands were quantified with a Bio-Rad GS-700 Imaging Densitometer. Each P-ERK value was normalized to total ERK level. The time of exposure of the Western blots chosen to illustrate the level of P-ERK and ERK are different in all of the figures.
Results
Mouse Transgenic Lines Overexpressing D2L or D2S Receptors. The physiological relevance of the two different isoforms on dopamine (DA)-mediated signaling is still unknown. Modifications of the D2L͞D2S ratio might affect D2R-controlled functions. The pituitary gland, and in particular the lactotrops, represent an interesting model to address this question because evaluation of PRL levels, both at the mRNA and protein levels, represents an easy readout of D2R-mediated activities. Two transgenic constructs were generated in which mouse D2L or D2S cDNAs were placed under the control of the 3-kb upstream region of the rat prolactin promoter (18, 23) (Fig. 1 A) . The polyadenylation (pA) site of the SV40 virus (19) was added at the 3Ј extremity of the D2R cDNAs, which allowed the transgenes to be recognized easily from the endogenous D2R gene in vivo. Among several lines obtained and characterized, we chose two lines having integrated an equal number of transgene copies (30 copies), indicated here as PRL-D2L and PRL-D2S, to perform our studies. The presence and integrity of the constructs in transgenic mice tail DNA were analyzed by Southern blot by using the SV40 pA site as probe (Fig. 1B) . Northern blot analysis of RNA prepared from different tissues revealed specific expression of the transgene only in the pituitary of both PRL-D2S and PRL-D2L mice (Fig. 1C) . In situ hybridization on transgenic mouse pituitaries showed a clear colocalization in lactotrops of D2R and PRL probes (data not shown), in agreement with the specific expression of PRL promoter only in lactotrops (18, 23) .
Overexpression of D2L and D2S was confirmed, at the mRNA and protein levels by performing RNase protection (Fig. 1D ) and ligand-binding assays (Fig. 1E) . RNase protection analyses showed that, whereas in the WT the D2L:D2S ratio is 8:1, in PRL-D2L it becomes 24:1 and in PRL-D2S 1:20. Ligand-binding assays supported these data showing a 3-fold increase in the number of D2-binding sites (B max ) in the pituitary of both transgenic mice lines as compared with WT littermates (Fig. 1E ) and similar affinity (K d ) for spiperone in all groups (Fig. 1E) .
These results also indicate that although D2R-mediated signaling negatively modulates the PRL promoter, this regulation is not sufficient to counteract completely the expression of the transgenes.
Modified Pituitary Anatomy in Transgenic Mice. Next we analyzed the influence of the increase of either D2L or D2S sites on the pituitary of transgenic animals. Macroscopic observations of the pituitary glands from transgenic and WT female mice showed a clear reduction in size of the pituitary anterior lobe in PRL-D2S mice in comparison with mice of WT and PRL-D2L genotype ( Fig. 2A) , which was evidenced by a 15% reduction in the weight of PRL-D2S pituitaries (1.95 Ϯ 0.1, n ϭ 4) in comparison with those of WT and PRL-D2L mice (2.3 Ϯ 0.15, n ϭ 4). In situ hybridizations with a mouse PRL probe on pituitaries from 4-month-old WT, PRL-D2L, and PRL-D2S female mice were performed. PRL mRNAs both by in situ hybridization and Northern analysis were reduced by almost 80% in PRL-D2S pituitaries as compared with WT and PRL-D2L glands (Figs. 2B and 3C), in agreement with an inhibitory role of D2S on PRL synthesis. We also analyzed the presence of possible alterations of the thyrotrop and somatotrop cells. These two cell types belong to the same lineage and are precursors of the lactotrops (24) (25) (26) . In situ hybridizations performed by using the ␤-thyroidstimulating hormone and growth hormone probes showed no difference either in the number of thyrotrops and somatotrops or in the level of expression of the hormones they produced (Fig. 2B). Similarly, analyses of the gonadotrops and corticotrops of transgenic pituitaries by using specific probes did not reveal differences as compared with WT pituitaries (data not shown).
Parallel immunofluorescence analyses performed on these pituitaries by using an antibody directed against PRL showed a 50% decrease in the lactotrop number in the anterior lobe of PRL-D2S versus WT (Fig. 3 A and B) . Conversely, a trend toward an increase of the lactotrop cell population was noticed in the PRL-D2L mice, although after quantification this increase never reached statistical significance. In agreement with in situ hybridization data, a strong decrease of PRL mRNA was observed by Northern blot analysis in PRL-D2S mice as compared with PRL-D2L and WT pituitaries (Fig. 3C) . In addition to PRL synthesis, DA also controls PRL release (5). Thus, we measured PRL plasma levels in animals of the three genotypes by RIA (Fig. 3D) . PRL plasma levels were reduced by 70% in PRL-D2S mice as compared with WT littermates, reflecting the reduction of lactotrops. Surprisingly, we found a significant 50% increase of PRL levels in PRL-D2L mice, which seems very likely dependent on an increase of PRL release.
These results suggest that overexpression of either D2L or D2S differently affects PRL synthesis and release. Furthermore, although D2S overexpression has a strong inhibitory effect both on PRL mRNA expression and lactotrop proliferation, D2L only affects PRL release. (27) (28) (29) (30) and in vivo (31) . Furthermore, ERK activation has been correlated with growth arrest or proliferation depending of the cellular type (32) .
Lactotrop Proliferation and ERKs Activation. Ligand activation of the D2R elicits a rapid phosphorylation of ERKs both in vitro
MMQ cells, a lactotrop cell line endogenously expressing functional DA D2 receptors (Fig. 4A) (33, 34) , were used to investigate whether the MAPK pathway might modulate lactotrop proliferation. Cells were treated with bromocriptine, a specific D2R agonist at the concentration of 500 nM (35) .
Activation of the MAPK pathway was assessed by Western blot analyses by using specific phospho-ERKs antibodies. An increase of ERK phosphorylation is observed 15 min after bromocriptine was added to the medium (Fig. 4B) . The activation is still sustained 1 h after the addition of the compound and disappears after 16 h. To analyze whether activation of the MAPK pathway has consequences on lactotrop cell proliferation, cells were incubated with [ 3 H]thymidine 16 h after bromocriptine addition, harvested after three additional hours, and the radioactivity measured. A significant reduction (40%) in the incorporation of tritiated thymidine was observed in bromocriptine-treated MMQ cells (Fig. 4C ). This effect was completely blocked by haloperidol, a D2R-specific antagonist (Fig. 4D) . To establish the link between ERKs activation and lactotrop proliferation, we used PMA, a well established stimulator of ERKs phosphorylation (36, 37) . Addition of 100 nM PMA to the cells resulted into a strong activation of ERKs phosphorylation (Fig.  4B) . The kinetics of ERK phosphorylation elicited by PMA and bromocriptine followed a similar time course. PMA also induced a 52% reduction of thymidine incorporation in MMQ cells (Fig.  4C) . bromocriptine effect on cell proliferation is blocked by pretreatment with U0126 or PD98059, two specific inhibitors of ERKs activation, whereas no effect was observed by using the SB203580, a specific inhibitor of the p38 kinase (Fig. 4D) . These data clearly indicate that in lactotrops the activation of the ERK pathway by D2R stimulation is involved in the control of the proliferation rate of these cells. Ro318220, a selective inhibitor of protein kinase C (PKC), is also able to revert bromocriptine effect (Fig. 4D) suggesting a possible role of PKC activation in D2R signaling. Similarly, the PMA-induced proliferation was partially blocked by pretreatment with U0126, PD98059, and Ro318220 (data not shown). These data indicate that stimulation of the MAPK pathway by D2R leads to a significant reduction of proliferation in a lactotrop cell line.
Is ERKs Phosphorylation D2R Isoform-Dependent in Vivo?
Western blot analyses with pituitary anterior lobe extracts from transgenic and WT female mice showed a clear increase of ERKs phosphorylation (P-ERK) specifically in PRL-D2S (Fig. 5A ), but not in PRL-D2L animals. Quantification of these results showed a 75% increase of P-ERKs in PRL-D2S compared with WT littermates and PRL-D2L mice (n ϭ 8) (Fig. 5B) . Induction of ERKs phosphorylation in PRL-D2S mice (Fig. 5 A and B) and the observed reduction in lactotrops number (Fig. 3 A and B) correlate well with our in vitro data (Fig. 4) . In particular, activation of ERKs seems to be strictly correlated with the overexpression of the D2S isoform. The role of D2S in the control of MAPK activation was further analyzed measuring the P-ERK level in the anterior lobe of D2LϪ͞Ϫ mice (15) . In these mice the total number of D2R sites are formed by D2S. In agreement with the results obtained in PRL-D2S transgenic mice, we found a 40% increase of ERK in the anterior lobes of D2LϪ͞Ϫ mice as compared with WT littermates (Fig. 5 C and D) .
Thus, these data show that in vivo, changing the physiological D2L͞D2S ratio in favor of D2S leads to an increased activation of the MAPK pathway by DA under basal conditions.
Reduced Levels of P-ERK and Abnormal Pituitary Proliferation in D2R؊͞؊
Mice. The hypoplasia observed on overexpression of the D2S isoform in PRL-D2S mice prompted us to revisit the pituitary tumor phenotype observed in the D2R-null mice (2) to evaluate the state of ERK phosphorylation in lactotrops lacking all forms of D2R.
Western blot analyses of pituitary extracts prepared from anterior lobes of 8-month-old D2RϪ͞Ϫ and WT female mice were performed. A 60% significant decrease in the levels of P-ERKs was found in the anterior lobe of D2RϪ͞Ϫ as compared with WT female littermates (Fig. 5 E and F) . To test whether the reduced phosphorylation of ERKs is a secondary event in tumor formation or a primary consequence of the absence of D2R, we also analyzed P-ERKs levels in young females, which do not exhibit pituitary hyperplasia yet (2) . Protein extracts were prepared from the anterior lobes of 2-month-old females of both genotypes. Western blot analysis revealed a 30% reduction of ERKs phosphorylation in young female D2RϪ͞Ϫ mice as compared with their WT siblings (Fig. 5 E and F) . The lower reduction of ERKs phosphorylation in young compared with older D2RϪ͞Ϫ females thus correlates with the advancing state of the hyperplasia.
Discussion
DA is a key regulator of lactotrop functions. The analysis of mutants lacking of D2R (2, 6) or the DA transporter (38) , elucidated an additional function related to the control of lactotrop cell proliferation. Indeed, absence of control by DA as in D2RϪ͞Ϫ mice or high level of DA as in DA transporter-null mice, lead to the development of tumors of lactotrop origin (prolactinomas) or to pituitary hypoplasia, respectively. The mechanisms underlying this control are of both a biological and a therapeutical interest because prolactinomas are frequent tumors in humans. In addition to the inhibition of the adenylyl cyclase, D2R has been reported to regulate other transduction pathways also (3) leading to the elevation of intracellular calcium as well as in the activation of PKC and MAPK pathways (3, 27) . The presence of two isoforms of D2R, expressed in a ratio that favors D2L with respect to D2S in the pituitary, questions its physiological significance. To address this issue we have altered this ratio by generating transgenic mice overexpressing either D2L or D2S in the lactotrops.
Overexpression of D2L and D2S Differently Affects Lactotrop Number
and PRL Levels. Our data show that overexpression of either D2L or D2S differently affects lactotrop physiology in vivo. This overexpression has a major impact on the regulation of PRL secretion. Indeed, the strong reduction of PRL observed in PRL-D2S mice indicates that D2S is very likely the isoform regulating PRL synthesis and lactotrop cell number. On the other hand D2L activation plays a major role in the regulation of PRL release. Therefore, we propose that in WT mice a strict control over the D2L͞D2S ratio is required to maintain a normal lactotrop number and PRL synthesis, very likely due to D2S, and release mainly controlled by D2L. Estrogen treatment of normal mice, which leads to an increase of PRL levels, has also been reported to increase the ratio of the D2 isoforms toward D2S. It might be speculated that the estrogen-induced increase of D2S might help negatively regulate PRL synthesis and lactotrop proliferation (39) .
D2R-Dependent ERKs Phosphorylation in Lactotrops.
The implication of MAPK pathway in the signaling mediated by D2R has recently been proposed both in vitro (27) (28) (29) and in vivo (31) . Our experiments on MMQ cells show that bromocriptine stimulation of D2R results in a prolonged activation of ERKs and in a concomitant reduction of the proliferation rate of these cells. These effects are blocked by haloperidol and by specific MEK1͞2 inhibitors, but not by a specific p38 kinase inhibitor. ERK phosphorylation induced by the stimulation of D2R in MMQ cells is mediated by PKC activation as it is in the brain (27) , because it is abolished by a specific PKC inhibitor. The time course of MAPK phosphorylation seems to be a direct indicator of cell cycle progression. Prolonged kinetics of activation of this pathway have been related to effects on cell differentiation, whereas rapid kinetics have been linked to proliferation (40) . Our results on MMQ cells strengthen these reports and support the notion that a sustained activation of ERKs phosphorylation is accompanied by a reduction of the proliferation rate. It is thus tempting to speculate that D2R activation of the MAPK pathway in vivo follows the same mechanism.
ERK Activation in the Control of Lactotrop Cell Proliferation. Overexpression of D2S leads to the development of hypoplastic pituitaries in which the level of phosphorylated ERKs is significantly increased as compared with WT or PRL-D2L mice. This finding is also supported by the observation of a higher basal level of P-ERK in the anterior lobe of D2LϪ͞Ϫ mice (15) , where all of the D2R sites are composed by D2S.
The tight correlation between ERKs phosphorylation and lactotrop proliferation is further supported by the analysis of D2RϪ͞Ϫ mice, where the basal level of ERKs phoshorylation is significantly decreased as compared with their WT littermates. This phenomenon is dependent on the absence of D2R- mediated signaling and is not a consequence of the hyperplasia present in D2R-null mice. Indeed, the reduction of ERKs phosphorylation in D2RϪ͞Ϫ mice is present also in young D2RϪ͞Ϫ females at stages in which the hyperplasia is not yet developed. The lower level of P-ERKs in old versus young females might be explained either by the higher number of lactotrops present in the tumor or by the selection of a lactotrop population having some proliferative advantages. Interestingly, overexpression of D2L in PRL-D2L mice does not lead to MAPK activation.
We have previously shown that D2L and D2S have distinct functions in vivo in the CNS (15, 16) , which seems to be the case also in the pituitary. Indeed, overexpression of the D2 isoforms differently affects the MAPK pathway, lactotrop cell proliferation, and PRL levels.
It might be speculated that through the interaction with different G proteins (41, 42) , D2L might mainly exert its effect through a direct coupling with ion channels facilitating hormone release, whereas D2S would control PRL levels, principally at the mRNA level, through a preferential interaction with the cAMP pathway. The increased PRL release or the stronger activation of the ERK pathway observed in presence of overexpressed D2L or D2S receptors in transgenic mice suggests that altering the natural balance between D2S and D2L pushes toward a specific signaling route. In these conditions D2 isoforms might acquire specificity or better affinities for particular G proteins or effectors.
Overexpression of a single D2 isoform in the absence of the other, either in vitro (27, 40) or in vivo, might alter the signaling normally mediated by the presence of the two isoforms. This finding is also inferred by our preliminary results, because mating of D2RϪ͞Ϫ with PRL-D2L or PRL-D2S transgenic mice leads in both cases to lactotrop hypoplasia and a concomitant increase of P-ERKs (T.A.S., C.I., and E.B., unpublished observations). In these mice, however. the overexpression of each isoform in lactotrops is very likely paralleled by high DA level. Indeed, lack of D2R in knockout mice results in the loss of autoreceptor functions regulating DA release (43) . It is thus conceivable that a higher level of DA released in the portal vein system of D2RϪ͞Ϫ mice upon physiological stimulation of hypothalamic DA neurons together with isoform overexpression in D2RϪ͞Ϫ PRL-D2L or D2S mice leads to the described phenotype. The dependence of D2R-mediated signaling on a fixed D2L͞D2S ratio strongly suggest an interaction between the two isoforms. Many aspects of D2 receptor physiology are still to unravel. Whether interference exist between D2L and D2S mRNAs for their translation, in the mechanisms regulating the trafficking of these isoforms at the membrane and whether D2L and D2S might heterodimerize in vivo is still not known. However, it seems that both receptors, in an adequate ratio, are required for the full expression of D2 normal functions. Future studies shall be aimed at identifying the functional relationship between the two D2 receptor isoforms, as well as their signaling cross-talk.
